---

---

sector : Health care and social assistance    tags : Trial   

save search

---

Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
BIOR | $0.6199 -2.99% -3.08% 180K |

Health Care and Social Assistan...

| -16.23% | O: 1.34% H: 0.0% C: -4.21%
bt-600 positive trial therapeutics results platform

---

Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
Published: 2022-03-21 (Crawled : 14:20) - globenewswire.com
VRDN | $13.04 -8.49% -9.28% 770K |

Health Care and Social Assistan...

| -34.92% | O: 0.75% H: 6.59% C: 1.34%
vrdn-002 disease antibody treatment thyroid eye trial therapeutics

---

BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting
Published: 2023-03-07 (Crawled : 21:00) - globenewswire.com
FNCTF | News | $11.16 -20.84% 130 |

Communications

| Email alert Add to watchlist
BICX | $0.75 201.91% 4.2K |

Health Care and Social Assistan...

| Email alert Add to watchlist
meeting trial positive results phase 1

---

BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Published: 2023-01-19 (Crawled : 14:20) - biospace.com/
BICX | $0.75 201.91% 4.2K |

Health Care and Social Assistan...

| -33.33% | O: 3.25% H: 0.0% C: 0.0%
bicx104 treatment opioid trial study

---

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)
Published: 2023-01-08 (Crawled : 16:20) - globenewswire.com
VRDN | $13.04 -8.49% -9.28% 770K |

Health Care and Social Assistan...

| Email alert Add to watchlist
vrdn-001 ongoing thyroid disease eye trial positive phase 1

---

Viridian Therapeutics Announces First Patient Enrolled in the ‘THRIVE’ Phase 3 Trial in Patients With Thyroid Eye Disease
Published: 2022-12-21 (Crawled : 13:00) - biospace.com/
VRDN | $13.04 -8.49% -9.28% 770K |

Health Care and Social Assistan...

| -52.65% | O: 0.18% H: 7.62% C: 7.15%
thyroid disease eye trial therapeutics

---

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
Published: 2022-11-14 (Crawled : 12:00) - globenewswire.com
VRDN | $13.04 -8.49% -9.28% 770K |

Health Care and Social Assistan...

| -36.47% | O: -2.49% H: 6.5% C: 1.6%
vrdn-001 ongoing thyroid disease eye trial positive phase 1

---

Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting
Published: 2022-10-22 (Crawled : 20:20) - globenewswire.com
VRDN | $13.04 -8.49% -9.28% 770K |

Health Care and Social Assistan...

| Email alert Add to watchlist
vrdn-001 ongoing thyroid disease active meeting eye trial positive

---

BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Published: 2022-10-13 (Crawled : 13:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130 |

Communications

| 23.59% | O: -4.1% H: 0.0% C: 0.0%
bicx104 treatment opioid trial

---

BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Published: 2022-06-30 (Crawled : 17:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130 |

Communications

| -5.93% | O: 1.06% H: 0.0% C: 0.0%
BICX | $0.75 201.91% 4.2K |

Health Care and Social Assistan...

| -64.81% | O: 6.44% H: 0.81% C: 0.81%
bicx104 treatment opioid trial

---

BioCorRx Begins Recruitment for Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Published: 2022-04-27 (Crawled : 13:20) - biospace.com/
BICX | $0.75 201.91% 4.2K |

Health Care and Social Assistan...

| Email alert Add to watchlist
FNCTF | News | $11.16 -20.84% 130 |

Communications

| Email alert Add to watchlist
bicx104 treatment opioid trial

---

BioCorRx Announces IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Published: 2022-03-16 (Crawled : 13:30) - biospace.com/
BICX | $0.75 201.91% 4.2K |

Health Care and Social Assistan...

| -77.29% | O: 0.83% H: 0.0% C: 0.0%
bicx104 treatment implant order trial approval trex one opioid

---

BioCorRx Announces Orange County Research Center as Clinical Trial Site for First-In-Human Clinical Trial of BICX104
Published: 2022-02-14 (Crawled : 14:30) - biospace.com/
BICX | $0.75 201.91% 4.2K |

Health Care and Social Assistan...

| -79.5% | O: 0.0% H: 5.0% C: 4.75%
bicx104 research trial

---

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)
Published: 2021-12-20 (Crawled : 13:30) - biospace.com/
VRDN | $13.04 -8.49% -9.28% 770K |

Health Care and Social Assistan...

| -36.69% | O: 0.1% H: 0.0% C: -3.4%
vrdn-001 eye eye disease trial therapeutics disease phase 1 phase 2

---

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M |

Consumer Services

BOF | $1.99 70.09% 41.21% 110M |

ILAG | $0.51 6.03% 40.62% 1.7M |

LICN | $0.941 68.04% 40.49% 15M |

AMST | $3.31 65.5% 39.58% 70M |

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M |

Technology Services

WIMI | $1.15 58.53% 36.92% 19M |

Technology Services

AIH | $0.45 12.5% 30.92% 320K |

Health Services

MULN | News | $3.78 38.46% 27.78% 13M |

Information

RILY | $29.86 37.48% 27.26% 12M |

Finance

---

Your saved searches

---